Home › Funds › TWIN FOCUS CAPITAL PARTNERS, LLC › MRNA
TWIN FOCUS CAPITAL PARTNERS, LLC position in MRNA
MODERNA INC · Health Care
TWIN FOCUS CAPITAL PARTNERS, LLC reported holding 185,480 shares of MRNA (MODERNA INC) in its Q3 2026 13F filing — a position valued at US$35.7M, representing 3.32% of its reported portfolio and ranking #6 among its reported holdings. TWIN FOCUS CAPITAL PARTNERS, LLC has disclosed MRNA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How TWIN FOCUS CAPITAL PARTNERS, LLC's MRNA position evolved
TWIN FOCUS CAPITAL PARTNERS, LLC first disclosed a stake in MRNA in Q4 2025 at 185,480 shares (US$5.5M). The position peaked in Q3 2026 at 185,480 shares, worth US$35.7M. Across 4 filings, TWIN FOCUS CAPITAL PARTNERS, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 185,480 shares valued at US$35.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 185.48K | $5.47M | New |
| Q1 2026 | 185.60K | $9.43M | Hold |
| Q2 2026 | 185.60K | $13.00M | Hold |
| Q3 2026 | 185.48K | $35.72M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MRNA and 13F data
MRNA (MODERNA INC) is a Health Care company. 42 other funds we track also report a position in MRNA — the largest reported positions include Fidelity Management & Research (FMR) (US$11.35B), Capital World Investors (US$4.36B), Baillie Gifford & Co (US$2.20B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MRNA
- Fidelity Management & Research (FMR) 58.96M sh · $11.35B · Q3 2026
- Capital World Investors 22.64M sh · $4.36B · Q3 2026
- Baillie Gifford & Co 11.44M sh · $2.20B · Q3 2026
- Theleme Partners LLP 6.66M sh · $1.28B · Q3 2026
- IMC-Chicago, LLC 3.07M sh · $590.92M · Q3 2026
- Merck & Co., Inc. 2.31M sh · $444.49M · Q3 2026
- BANQUE PICTET & CIE SA 2.15M sh · $414.27M · Q3 2026
- Flagship Pioneering, LLC 4.63M sh · $324.39M · Q2 2026
- a16z Perennial Management, L.P. 1.52M sh · $292.57M · Q3 2026
- Douglas Lane & Associates, LLC 1.16M sh · $223.56M · Q3 2026
- Beau Ventures, LLc 1.00M sh · $192.58M · Q3 2026
- Lingotto Investment Management LLP 749.21K sh · $144.27M · Q3 2026
More on TWIN FOCUS CAPITAL PARTNERS, LLC
FAQ
How long has TWIN FOCUS CAPITAL PARTNERS, LLC held MRNA?
TWIN FOCUS CAPITAL PARTNERS, LLC has disclosed MRNA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is TWIN FOCUS CAPITAL PARTNERS, LLC's current position in MRNA?
As of Q3 2026, TWIN FOCUS CAPITAL PARTNERS, LLC holds 185.48K shares of MRNA (MODERNA INC), valued at $35.72M, representing 3.32% of its reported portfolio and ranking #6.
Has TWIN FOCUS CAPITAL PARTNERS, LLC been buying or selling MRNA?
In the latest 13F filing (Q3 2026), TWIN FOCUS CAPITAL PARTNERS, LLC held unchanged its position in MRNA. The position peaked in Q3 2026 at 185.48K shares.
Which other funds hold MRNA?
Other major institutional holders of MRNA include Fidelity Management & Research (FMR), Capital World Investors, Baillie Gifford & Co, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.